Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-325.66	-342.99	-234.63	-183.12	-250.22	-204.47
Depreciation & Amortization	14.17	19.63	20.25	18.02	13.62	4.29
Loss (Gain) From Sale of Assets	4.43	1.34	1.51	0.1	1.21	-4.88
Asset Writedown & Restructuring Costs	139.92	138.48	-	-	-	-
Loss (Gain) From Sale of Investments	-2.79	-1.71	3.33	1.15	38.35	0.54
Stock-Based Compensation	24.34	33.14	47.08	81.92	62.2	33.26
Other Operating Activities	-8.9	-7.17	-4.65	-5.62	4.57	10.72
Change in Accounts Payable	-4.7	-3.23	1.46	0.67	0.09	-0.28
Change in Unearned Revenue	-	-	-	-84.65	-10.51	-7.76
Change in Other Net Operating Assets	-5.83	0.11	1.96	1.97	14.43	7.7
Operating Cash Flow	-165.02	-162.39	-163.69	-169.56	-126.25	-160.87
Capital Expenditures	-0.52	-0.46	-2.69	-24.28	-65.5	-51.48
Cash Acquisitions	-31.35	-31.35	-	-	-	-
Investment in Securities	170.57	154.23	186.73	12.74	-56.07	-222.04
Investing Cash Flow	138.97	122.42	184.05	-11.54	-121.57	-273.52
Issuance of Common Stock	50.62	1.4	2.2	11.1	401.24	0.37
Repurchase of Common Stock	-	-0.08	-0.46	-0.46	-	-11.81
Financing Cash Flow	50.62	1.33	1.74	10.64	401.24	476.79
Net Cash Flow	24.57	-38.64	22.1	-170.46	153.42	42.4
Free Cash Flow	-165.54	-162.86	-166.38	-193.83	-191.75	-212.36
Free Cash Flow Margin	-403743.90%	-266980.33%	-127984.62%	-228.89%	-1800.50%	-2737.94%
Free Cash Flow Per Share	-10.71	-12.46	-13.26	-15.69	-28.22	-320.34
Levered Free Cash Flow	-97.88	-67.56	-90.36	-53.9	-129.82	-128
Unlevered Free Cash Flow	-97.88	-67.56	-90.36	-53.9	-129.82	-128
Change in Working Capital	-10.53	-3.12	3.42	-82.02	4.01	-0.34

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q